期刊文献+

血小板活化因子及其乙酰水解酶在新生儿感染中的变化及临床意义 被引量:6

Changes and significance of platelet-activating factor and platelet-activating factor-acetylhydrolase in neonatal infection
下载PDF
导出
摘要 目的检测感染新生儿血浆血小板活化因子(PAF)水平及其乙酰水解酶(PAF-AH)的活性,探讨两者在新生儿感染中的变化及临床意义。方法以复旦大学附属儿科医院新生儿科病房收治的日龄<30d的新生儿为研究对象。依据感染部位和程度分为全身感染组、局部感染组及非感染组;依据日龄分为早期新生儿(≤7d)和晚期新生儿(>7d)。采集研究对象桡动脉血标本,对全身感染组中合并器官功能衰竭的患儿在感染的第1、3、5和7天增加采集桡动脉血标本。测定血浆PAF水平(μg.L-1)和PAF-AH活性(μmol.L-1.min-1)。分析感染程度、性别、日龄和出生体重对血浆PAF水平和PAF-AH活性的影响,比较不同感染组PAF水平和PAF-AH活性的差异,观察全身感染合并器官功能衰竭患儿血浆PAF水平和PAF-AH活性在病程1~7d的变化趋势。结果研究期间共收治247例新生儿,男146例,女101例;平均日龄9.2(1~57)d;平均胎龄35.85(27~43)周;平均出生体重2517(906~4750)g。全身感染组91例,局部感染组63例,非感染组93例。①新生儿血浆PAF水平与感染程度相关(P=0.000);血浆PAF-AH活性与感染程度及日龄(P均为0.000)相关。②全身感染组血浆PAF水平(9.5±8.1)显著高于局部感染组(5.3±3.2)及非感染组(4.6±3.5)。早期新生儿中,全身感染组血浆PAF-AH活性(5.7±2.7)显著低于局部感染组(7.3±2.9)和非感染组(7.3±2.5)。晚期新生儿中,全身感染组血浆PAF-AH活性(7.0±2.5)显著低于局部感染组(9.7±2.2)和非感染组(9.7±2.7)。③全身感染组合并器官功能衰竭的9/12例存活患儿在病程的1~7d血浆PAF水平呈下降趋势,PAF-AH活性呈上升趋势。3/12例死亡患儿中两者的变化趋势则相反。④全身感染组31/91例确诊败血症患儿中,革兰阴性菌感染者血浆PAF水平(13.1±11.0)显著高于革兰阳性菌感染者(5.4±3.9),PAF-AH活性(4.9±2.1)显著低于革兰阳性菌感染者(7.9±2.4)。结论新生儿严重感染时血浆PAF水平增高,PAF-AH活性降低,两者的变化趋势与预后相关。 Objective To evaluate the relationship between platelet-activating factor(PAF)/platelet-activating factor-acetylhydrolase(PAF-AH) and neonatal infection and to observe the trends of plasma PAF level and PAF-AH activities during the course of infection by measuring plasma PAF levels and PAF-AH activities in neonates with infection.Methods Neonates admitted to the neonatal ward of Children's Hospital of Fudan University from July to December in 2008 were enrolled.According to the locations and severity of infection,the patients were divided into 3 groups,general infection group,local infection group and non-infection group.Plasma samples of infection groups were taken within 48 h after infection,others were taken during hospitalization period.Besides,plasma samples were taken on the first,third,fifth and seventh day of infection from the neonates who had severe infection with organ dysfunction to observe the trends of plasma PAF levels and PAF-AH activities during the course of infection.The plasma PAF levels were measured by ELISA,and PAF-AH activities were measured using PAF Acetylhydrolase Assay Kit from Cayman Chemical Company.The plasma PAF levels(μg·L^-1) and PAF-AH activities(μmol·L^-1·min^-1) were compared in different groups and the changes of the plasma PAF levels and PAF-AH activities in severe general infection neonates were compared.Results Total 247(146 boys and 101 girls) neonates were enrolled in the study.Average age,gestational age and birth weight were 9.2(1~57)d,35.85(27~43)weeks and 2 517(906~4 750)g,respectively.General infection group,local infection group and non-infection group included 91,63 and 93 neonates,respectively.①Multiple linear regression analysis showed that the plasma PAF levels had relation with severity of infection(P=0.000),no relation with sex,gestional age,birth weight and age;The plasma PAF-AH activities had relation with severity of infection and age(both P=0.000),but had no relation with sex,gestational age and birth weight.The plasma PAF-AH activities were lower in early stage neonates than that in late stage neonates.②Mean plasma PAF levels were significantly higher in infants with general infection(9.5±8.1) than those in infants with non-infection group(5.3±3.2)and local infection group(4.6±3.5)(P=0.000).In early stage or late stage neonates,plasma PAF-AH activities of general infection group(5.7±2.7,7.0±2.5) were significantly lower than those of non-infection group(7.3±2.9,9.7±2.2,respectively) and local infection group(7.3±2.5,9.7±2.7,respectively).③The plasma PAF levels of 9/12 alive children with multiple organ dysfunction in the course of 1-7 d decreased and plasma PAF-AH activities increased.It was opposite in 3/12 deaths.④Infants with sepsis caused by Gram negative bacteria had higher plasma PAF levels and lower PAF-AH activities than those with sepsis caused by Gram positive bacteria(P=0.005).Conclusions Plasma PAF levels were positively correlated and PAF-AH activities were negatively correlated with the severity of infection.Plasma PAF levels and PAF-AH activities showed variations during the course of infection.The trends of variations may be correlated with the prognosis.
出处 《中国循证儿科杂志》 CSCD 2010年第2期130-134,共5页 Chinese Journal of Evidence Based Pediatrics
关键词 新生儿 感染 血小板活化因子 血小板活化因子乙酰水解酶 Neonate Infection Platelet-activating factor Platelet-activating factor-acetylhydrolase
  • 相关文献

参考文献17

  • 1Schuchat A, Zywicki SS, Dinsmoor M J, et al. Risk factors and opportunities for prevention of early-onset neonatal sepsis: a muhicenter case-control study. Pediatrics,2000, 105 ( 1 Pt 1 ) : 21-26.
  • 2Claus RA, Russwurm S, Dohm B, et al. Plasma plateletactivating factor acetylhydrolase activity in critically ill patients. Crit Care Med, 2005, 33(6) :1416-1419.
  • 3Gomes RN, Bozza FA, Amancio RT, et al. Exogenous plateletactivating factor acetylhydrolase reduces mortality in mice with systemic inflammatory response syndrome and sepsis. Shock, 2006, 26(1): 41-49.
  • 4Poeze M, Froon AH, Ramsay G, et al. Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, muhicenter, double-blind, randomized phase Ⅱ trial. TCV-309 Septic Shock Study Group. Shock, 2000,14(4) : 421-428.
  • 5Suputtamongkol Y, lntaranongpai S, Smith MD, et al. A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist ) in patients with severe sepsis. Antimicrob Agents Chemother, 2000, 44 (3) : 693 -696.
  • 6Vincent JL, Spapen H, Bakker J,et al. Phase Ⅱ multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis. Crit Care Med, 2000, 28 (3) :638-642.
  • 7Schuster DP, Metzler M, Opal S, et al. Recombinant plateletactivating factor acetylhydrolase to prevent acute respiratory dist~ss syndrome and mortality in severe sepsis: Phase Ⅱ b, multicenter, randomized, placebo-controlled, clinical trial. Crit Care Med, 2003, 31 (6):1612-1619.
  • 8Opal S, Laterre PF, Abraham E, et al. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase Ⅲ, muhicenter, randomized, doubleblind, placebo-controlled, clinical trial. Crit Care Med,2004, 32(2) :332-341.
  • 9中华医学会儿科学分会新生儿学组,余加林,吴仕孝.新生儿败血症诊疗方案[J].中华儿科杂志,2003,41(12):897-899. 被引量:1025
  • 10金汉珍 黄德岷 官希吉 主编.实用新生儿学:第3版[M].北京:人民卫生出版社,2001.7,57—65,400—411,818—882,762—771.

二级参考文献23

  • 1Schuchat A, Zywicki SS, Dinsmoor MJ, et al. Risk factors and opportunities for prevention early onset neonatal sepsis: a multi center case-control study. Pediatrics, 2000,105 : 21 -26.
  • 2Christ-Crain M, Morgenthaler N, Struck J, et al. Mid regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care, 2005, 9:RS16-R824.
  • 3Christ Crain M, Morgenthaler N, Stolz D, et al. Proadrenomedullin to predict severity and outcome in community acquired pneumonia. Crit Care, 2006, 10:R96.
  • 4Morgenthaler NG, Struck J, Alonso C. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem, 2005, 51:1823-1829.
  • 5周秦玉.坏死性小肠结肠炎//金汉珍,黄德珉,官希吉.实用新生儿学.3版.北京:人民卫生出版社,2001:508-513.
  • 6Wang P. Andrenomedullin and cardiovascular responses in sepsis. Peptides, 2001,22 :1835-1840.
  • 7Amara SG, Jonas V,Rosenfeld MG, et al. Alternative RNA processing in caleitonin gene expression generates mRNAs encoding different polypeptide products. Nature, 1982, 298: 240-244.
  • 8Jaye DL,Waites KB. Clinical applications of C-reactive protein in pediatrics. Pediatr Infect Dis J, 1997, 16:735-746.
  • 9Enguix A,Rey C,Concha A,et al. Comparison of procalcition with C- reaction protein and serum amyloid for the early diagnosis of bacterial sepsis in critically ill neonates and chil dren. Intensive Care Med, 2001, 27:211-215.
  • 10Meisner M. Pathobiochemistry and clinical use of procalcitonin, Clin Chim Acta,2002,323:17-29.

共引文献1045

同被引文献157

  • 1魏克伦,杨于嘉,姚裕家,杜立中,王庆红.中国住院新生儿流行病学调查[J].中国当代儿科杂志,2009,11(1):15-20. 被引量:207
  • 2陈丹,黄西林,李小萍.新生儿坏死性小肠结肠炎危险因素的Meta分析[J].中华临床医师杂志(电子版),2010,4(5):563-567. 被引量:22
  • 3张慧玉,刘瑞兰,庞保东,刘凤珍,岳爱红,田庆玲,戴秀华,韩宝生.血小板活化因子分解酶基因多态性在儿童过敏性紫癜中的意义[J].实用医学杂志,2006,22(3):303-304. 被引量:7
  • 4Edwards LJ, Constantinescu CS. Platelet activating factor/platelet activating factor receptor pathway as a potential therapeutic target in autoimmune diseases [ J ]. lnflamm Allergy Drug Targets, 2009,8 ( 3 ) : 182 - 190.
  • 5Jeong YI, Jung ID, Lee CM, et al. The novel role of platelet activating factor in protecting mice against lipopolysaccharide - induced endotoxic shock [ J ]. PLoS One,2009, 4 ( 8 ) : e6503.
  • 6Diana M. Stafforini, Biology of platelet - activating factor acetylhydrolase ( PAF - AH), lipoprotein associated phospholipase A2[J]. Cardiovasc Drugs Ther ,2009 ,23 ( 1 ) :73 - 83.
  • 7Detopoulou P, Nomikos T, Fragopoulou E, et al. Platelet activating factor (PAF) and activity of its biosynthetic and catabolic enzymes in blood and leukocytes of male patients with newly diagnosed heart failure[J]. Clin Biochem, 2009,42 ( 1 - 2 ) :44 - 49.
  • 8Stafforini DM, Satoh K, Atkinson DL, et al. Platelet activating factor acetylhydrolase deficieney. A missense mutati on near the activesite of anti - inflammatory phospholipase [ J ]. J Clin Invest, 1996, 9 ( 7 ) :2784 -2791.
  • 9Liu J, Chen R, Marathe GK,et al. Circulating platelet - activating factor is primarily cleared by transport, not intravascular hydrolysis by lipoprotein- associated phospholipase A2/PAF acetylhydrolase [ J ]. Circ Res,2011,108(4) :469 -477.
  • 10Renteria LS, Raj JU, Ibe BO. Prolonged hypoxia modulates platelet activating factor receptor - mediated responses by fetal ovine pulmonary vaseular smooth muscle cells [ J ]. Mol Genet Metab, 2010 , 101 (4) :400 - 408.

引证文献6

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部